TG Therapeutics Stock Price | TGTX Stock Quote, News, and History

August 2024 · 4 minute read

Feb. 04 2021 Mar. 05 2021

Download Reset

Loading..
DateOpenCloseDaily HighDaily Low

Price change over selected period: 0% 0

Total Analysts: 27

Buy Ratings: 19 Neutral Ratings: 5 Sell Ratings: 3

Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}

Price *Price Target

Lowest: 6.00 Median: 28.24 Highest: 49.00

All
 20242025202620272028
Revenue3104746208371,063
Dividend0.000.00---
Dividend Yield (in %)0.00 %0.00 %---
EPS-0.030.601.022.483.45
P/E Ratio-585.2432.8919.317.975.73
EBIT5105183445663
EBITDA30100160--
Net Profit-293165371518
Net Profit Adjusted9116212371518
Pre-Tax Profit-287181437656
Net Profit (Adjusted)0115250--
EPS (Non-GAAP) ex. SOE0.050.671.24--
EPS (GAAP)-0.030.601.022.483.45
Gross Income2574245959111,199
Cash Flow from Investing11-4900
Cash Flow from Operations-6142240441583
Cash Flow from Financing11-4900
Cash Flow per Share-0.150.881.12--
Free Cash Flow-159137202--
Free Cash Flow per Share-----
Book Value per Share1.311.563.10--
Net Debt-22-119-266--
Research & Development Exp.114124154193222
Capital Expenditure1613205370
Selling, General & Admin. Exp.156184193273314
Shareholder’s Equity200268549--
Total Assets384539707--
 Previous Quarter
ending 06/30/24		Current Quarter
ending 09/30/24		Next Quarter
ending 12/31/24		Current Year
ending 12/31/24		Next Year
ending 12/31/25
Earnings Estimates
No. of Analysts77798
Average Estimate-0.046 USD-0.006 USD0.040 USD-0.034 USD0.601 USD
Year Ago-0.337 USD0.797 USD-0.101 USD0.089 USD-
Publish Date8/7/202411/12/20243/4/2025--
Revenue Estimates
No. of Analysts77788
Average Estimate66 USD78 USD91 USD310 USD474 USD
Year Ago16 USD166 USD44 USD234 USD-
Publish Date8/7/202411/12/20243/4/2025--

* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

DateNameDividend*yieldCurrency
2023TG Therapeutics Inc0.000.00USD
2022TG Therapeutics Inc0.000.00USD
2021TG Therapeutics Inc0.000.00USD
2020TG Therapeutics Inc0.000.00USD
2019TG Therapeutics Inc0.000.00USD
2018TG Therapeutics Inc0.000.00USD
2017TG Therapeutics Inc0.000.00USD
2016TG Therapeutics Inc0.000.00USD
2015TG Therapeutics Inc0.000.00USD
2014TG Therapeutics Inc0.000.00USD
2013TG Therapeutics Inc0.000.00USD
2012TG Therapeutics Inc0.000.00USD
2011TG Therapeutics Inc0.000.00USD
2010TG Therapeutics Inc0.000.00USD
2009TG Therapeutics Inc0.000.00USD

*Yield of the Respective Date

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

Risk

Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’sbalance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of creditrisk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes intoaccount day-to-day movements in market value compared to a company’s liability structure.

Ownerin %
Freefloat89.11
The Vanguard Group, Inc.8.85
Vanguard Group, Inc. (Subfiler)8.50
Michael Sean Weiss8.46
SSgA Funds Management, Inc.5.34
State Street Corp.5.04
Jefferies Financial Group Inc. (Investment Management)3.30
BlackRock Fund Advisors3.19
Maverick Capital Ltd.2.79
Vanguard Total Stock Market ETF2.79
BlackRock Institutional Trust Co. NA2.68
Darwin Global Management Ltd.2.62
Darwin Global Management Ltd.2.62
Vanguard Small Cap Index Fund2.26
SPDR S&P Biotech ETF2.26

Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

ncG1vNJzZmilkae4psDSZ5muq5mjsrS%2FyKeqopyVp3uku8xoqq2nk6DAcMDGra9mq6SksKw%3D